If you need help accessing our website, call 855-698-9991
Skip to main content
NYU Langone Provider

Paul Saenger, MD

NYU Langone Provider
  • Specialty: Pediatric Endocrinology
  • Treats: Children
  • Language: English
  • Phone: 516-663-4600
Schedule Appointment

I first became interested in medicine during high school. I was drawn to pediatric endocrinology because I thought it would be rewarding to help children with chronic disease to grow, live, and thrive.

I treat patients with growth disorders, diabetes mellitus, and disorders of puberty and the thyroid. I take care of both children and their families. I help them formulate realistic expectations and cope with their diagnoses.

I have more than 40 years of experience in the field and have trained more than 45 fellows who are now working in pediatric endocrinology.


Conditions and Treatments

Conditions
  • hashimoto's disease
Conditions
  • achondroplasia
  • adrenal gland disorders
  • autoimmune thyroid disease
  • chronic thyroiditis
  • delayed puberty
  • growth hormone deficiency
  • hypopituitarism
  • hypothyroidism
  • klinefelter syndrome
  • obesity
  • polycystic ovary syndrome
  • short stature
  • thyroiditis
  • turner syndrome

Positions
  • Clinical Assistant Professor, Department of Pediatrics at NYU Grossman Long Island School of Medicine
Board Certifications
  • American Board of Pediatrics (Pediatric Endocrinology), 1978
  • American Board of Pediatrics - Pediatrics, 1973
Education and Training
  • Fellowship, New York Hospital/Cornell Medical Center, Pediatric Endocrinology, 1974
  • Residency, Montefiore Medical Center, 1971
  • MD from University Of Munich, 1967

Is this your profile?

Edit profile

Paul Saenger, MD does not accept insurance.

  • Pfizer Registry of Outcomes in Growth hormone RESearch (PROGRES): A Multi-Country Non-Interventional Prospective Cohort Study Among Patients with Human Growth Hormone (hGH) Treatments Under Routine Clinical Care

    Learn More
  • NN8640-4245 - A dose-finding trial evaluating the effect and safety of once-weekly treatment of somapacitan compared to daily Norditropin in children with short stature born small for gestational age with no catch-up growth by 2 years of age or older

    Learn More
  • A PHASE 3 OPEN-LABEL RANDOMIZED MULTICENTER 12 MONTHS EFFICACY AND SAFETY STUDY OF WEEKLY MOD-4023 COMPARED TO DAILY GENOTROPIN THERAPY IN PRE-PUBERTAL CHILDREN WITH GROWTH HORMONE DEFICIENCY

    Learn More
View All Research Studies (3)

Read All Publications (114)